用于儿童克罗恩病的抗体药物临床研究进展

Clinical Research Progress of Antibody Drugs for Pediatric Crohn's Disease

克罗恩病(CD)是一种慢性非特异性肠道炎症性疾病,发病机制复杂。近年来,儿童CD的发病率逐年上升。与成人患者相比,CD患儿的病程发展更快,手术治疗率更高,且面临更高的远期并发症风险。随着对CD发病机制的深入了解,作用于肿瘤坏死因子α、白细胞介素及整合素等靶点的新型抗体药物不断问世,为儿童CD患者提供了更多的用药选择。总结了CD的病理生理机制,并对各类抗体药物在儿童CD患者中的有效性与安全性研究进行综述,旨在为CD治疗药物的研发及CD患儿临床合理用药提供参考。

Crohn’s disease(CD)is a chronic nonspecific intestinal inflammatory disease with a complex pathogenesis.In recent years,the incidence of pediatric CD has been increasing annually.Compared with adult patients,children with CD experience a faster course of disease,a higher rate of surgical treatment,and a higher risk of long-term complications.With the in-depth understanding of the pathogenesis of CD,novel antibody drugs targeting tumor necrosis factorα(TNF-α),interleukins and integrins have emerged,providing more treatment options for pediatric CD patients.This article summarized the pathophysiological mechanism of CD,and studies on the efficacy and safety of various antibody drugs in children with CD,aiming to provide references for the development of CD treatments and clinical rational drug use in CD pediatric patients.